<DOC>
	<DOC>NCT00078819</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis. This is a Phase 3 blinded, placebo-controlled study.</brief_summary>
	<brief_title>Etanercept (Enbrel®) in Psoriasis - Pediatrics</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients with plaque psoriasis Patient may not receive certain psoriasis medications during the study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pediatric Psoriasis</keyword>
</DOC>